Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Trazodone Interaction: Monitor | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Trazodone

Serotonin Antagonist & Reuptake Inhibitor | Sleep Aid

Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Trazodone?

Yes, but with caution. Both LGD-4033 and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). Regular monitoring is advised.

Is LGD-4033 and Trazodone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: blood pressure raising, teratogenic. Monitor accordingly.

What are the interactions between LGD-4033 and Trazodone?

Both LGD-4033 and Trazodone can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar). This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Trazodone?

LGD-4033 has a half-life of ~24-36 hours and Trazodone has a half-life of ~5-9 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Enhances memory consolidation and spatial learning in animal models through FGFR1-mediated synaptic plasticity. Preclinical evidence suggests potential to counteract age-related cognitive decline via neurogenesis and synaptic support. Animal studies demonstrate reduced infarct volume and improved functional outcomes following ischemic injury. Shows protective effects in preclinical models of Alzheimer's disease and other neurodegenerative conditions. Promotes long-term potentiation and strengthens synaptic connections through FGFR1 activation. Stimulates the generation of new neurons in the hippocampus in animal models.

Source: peptide-db.com ↗

Research Indications

ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss. ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss. Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%). 91% achieved near-normal blood sugar levels versus 42% with placebo. ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%. Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Telmisartan is administered exclusively via the oral route as a tablet. It reaches peak plasma concentration approximately 0.5-1 hour after administration, with absolute bioavailability of approximately 42-58% (dose-dependent). The drug is highly lipophilic, extensively protein-bound (>99.5%), and has a large volume of distribution (~500 L), contributing to its long duration of action. Telmisartan undergoes hepatic glucuronidation (not CYP450-dependent) and is eliminated primarily through biliary/fecal excretion, making it suitable for patients with mild to moderate renal impairment without dose adjustment. AAS Cycle - Cardiac Protection 40-80 mg/day Once daily Oral Mild Hypertension / Preventive Use 20-40 mg/day Standard Hypertension Treatment

Source: peptide-db.com ↗
Side effects

Common Side Effects

Nausea (mild-moderate, typically improves over time) Diarrhea Vomiting Increased heart rate (5-17 bpm observed)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides